Development and immunogenicity of a prototype multivalent Group B Streptococcus bioconjugate vaccine

Authors

Jeremy A Duke, University of Georgia
Amy V Paschall, University of Georgia
Lloyd S Robinson, VaxNewMo
Cory J Knoot, VaxNewMo
Evgeny Vinogradov, National Research Council Canada
Nichollas E Scott, University of Melbourne
Mario F Feldman, Washington University School of Medicine in St. Louis
Fikri Y Avci, University of Georgia
Christian M Harding, VaxNewMo

Journal

ACS Infectious Diseases

Publication Date

11-12-2021

Volume

7

Issue

11

First Page

3111

Last Page

3123

Document Type

Open Access Publication

DOI

10.1021/acsinfecdis.1c00415

Rights and Permissions

Duke JA, Paschall AV, Robinson LS, Knoot CJ, Vinogradov E, Scott NE, Feldman MF, Avci FY, Harding CM. Development and Immunogenicity of a Prototype Multivalent Group B Streptococcus Bioconjugate Vaccine. ACS Infect Dis. 2021 Nov 12;7(11):3111-3123. doi: 10.1021/acsinfecdis.1c00415. Copyright © 2021 The Authors. Published by American Chemical Society Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Recommended Citation

Duke, Jeremy A; Paschall, Amy V; Robinson, Lloyd S; Knoot, Cory J; Vinogradov, Evgeny; Scott, Nichollas E; Feldman, Mario F; Avci, Fikri Y; and Harding, Christian M, "Development and immunogenicity of a prototype multivalent Group B Streptococcus bioconjugate vaccine." ACS Infectious Diseases. 7, 11. 3111 - 3123. (2021).
https://digitalcommons.wustl.edu/oa_4/871

Additional Links

Supplemental material is available for this article at publisher site.